Clinical trials for Angiosarcoma
21 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS · PI: Varun Monga, MBBS
- RECRUITINGPhase 2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute · PI: Andrew Brohl, MD
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute · PI: Shushan Hovsepyan, MD
- RECRUITINGPhase 2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPhase 2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan · PI: Dai Ogata, M.D., Ph.D.
- RECRUITINGPhase 1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc. · PI: Glen Weiss, MD
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group · PI: Elena Palassini
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive · PI: jean-charles nault, Pr
- RECRUITINGPhase 2NCT06277154MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaHRYZ Biotech Co. · PI: Xing Zhang
- RECRUITINGPhase 1NCT05859074A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center · PI: Lara Dunn, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05601232A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMAStella Pharma Corporation
- RECRUITINGNCT07432932Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsRoyal Marsden NHS Foundation Trust · PI: Robin Jones, MD
- RECRUITINGPhase 2NCT05961761Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma PatientsNiels Junker · PI: Niels Junker, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04668300Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaM.D. Anderson Cancer Center · PI: Neeta Somaiah
- ACTIVE NOT RECRUITINGPhase 2NCT04339738Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaNational Cancer Institute (NCI) · PI: Juneko E Grilley-Olson
- RECRUITINGN/ANCT04055220Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasCentre Leon Berard · PI: Jean-Yves BLAY
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03921008Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous AngiosarcomaWashington University School of Medicine · PI: Anthony Apicelli, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT03860272Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc. · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 2NCT03331250Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Massachusetts General Hospital · PI: Gregory Cote, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT03069378A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaMemorial Sloan Kettering Cancer Center · PI: Ciara Kelly, MBBCh BAO
- RECRUITINGPhase 2NCT01042379I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerQuantumLeap Healthcare Collaborative · PI: Laura Esserman, MD, MBA